Localization of payload delivery systems to tumor sites via beacon cell targeting

Patent metadata

Field	Value
Publication number	US-12233168-B2
Application number	US-202017594193-A
Country	US
Kind code	B2
Filing date	Apr 8, 2020
Priority date	Apr 8, 2019
Publication date	Feb 25, 2025
Grant date	Feb 25, 2025

Abstract

Provided herein are compositions comprising nanoparticles, wherein the nanoparticles comprise at least one payload, wherein the nanoparticles further comprise at least one surface bound functional group and method of their use.

First claim

What is claimed is:

1. A method to target tumor-associated bacterial beacon cells in tumors of a subject comprising:
i) first administering to the subject Salmonella bacterial beacon cells that colonize tumors, and
ii) second administering to the subject nanoparticles having a payload and a functionable group that targets the colonized beacon cells of i).

2. A method to treat cancer in a subject in need thereof comprising:
i) first administering to the subject Salmonella bacterial beacon cells that colonize tumors, and
ii) second administering to the subject nanoparticles having a payload and a functionable group that targets the colonized beacon cells of i).

3. The method of claim 1 , wherein at least one of the functional groups is an antibody.

4. The method of claim 1 , wherein the payload or the nanoparticle comprises at least one of paclitaxel, albumin-based nanoparticle and paclitaxel, liposomal nanoparticle and doxorubicin, erlotinib, gefitinib, polymxin B, polymxin E, rituximab, bortezomib, rucaparib, sorafenib, liposomal nanoparticle and daunorubicin and cytarabine, liposomal doxorubicin, pegylated-liposomal nanoparticle formulation of doxorubicin, polymeric NP micelle formulation of paclitaxel or pegaspargase.

5. The method of claim 1 , wherein the Salmonella is an attenuated strain of Salmonella.

6. The method of claim 5 , wherein the attenuated strain of Salmonella is VNP20009.

7. The method of claim 1 , wherein the Salmonella is a strain of Salmonella Typhimurium.

8. The method of claim 7 , wherein the strain of Salmonella Typhimurium is an attenuated strain of Salmonella Typhimurium.

9. The method of claim 1 , wherein the bacteria occupy tumor tissue entirely or partially extracellular.

10. The method of claim 2 , wherein the bacteria occupy tumor tissue entirely or partially intracellular.

11. The method of claim 1 , wherein the nanoparticle comprises or is formed of organic substances or inorganic substances.

12. The method of claim 11 , wherein the substances comprise polymers, proteins, gold, silver, alumina, titania, and/or silica.

13. The method of claim 4 , wherein the payload is paclitaxel.

14. The method of claim 1 , wherein the nanoparticle is an albumin nanoparticle.

15. The method of claim 1 , wherein the functional group is an antibody which targets Salmonella.

16. The method of claim 1 , wherein the bacteria are attenuated Salmonella , the nanoparticle is an albumin nanoparticle and the functional group is an antibody which targets Salmonella.

17. The method of claim 1 , wherein the payload is a cancer treatment.

Assignees

• Univ Massachusetts

Inventors

• Forbes Neil S
• Van Dessel Nele
• Klier John
• Taylor Shane
• Raman Vishnu

Classifications

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title

• A61K47/6835

  the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site · CPC title

• A61K47/6935

  the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61P35/00

  Antineoplastic agents · CPC title